Abstracts

INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPHOID VS GI TISSUES

The majority of persistently HIV-infected cells in patients on suppressive antiretroviral therapy (ART) are in lymphoid tissue. Limited drug uptake by lymphoid tissues may contribute to sustained viral persistence. Identifying tissue sources with differential drug uptake may help guide future HIV eradication strategies. We measured plasma, gut mucosa, and peripheral lymph node drug concentrations from…

PLASMA AND INTRACELLULAR PK OF TENOFOVIR IN PATIENTS SWITCHED FROM TDF TO TAF

Tenofovir alafenamide (TAF), a pro-drug of tenofovir (TFV), has higher intracellular penetration and lower plasma concentrations than tenofovir disoproxil fumarate (TDF). Intraindividual comparisons of plasma and intracellular pharmacokinetics (PK) of TFV and its intracellular metabolite, tenofovir-diphosphate (TFV-DP) have not been described in patients switching from TDF to TAF. We conducted a prospective, non-randomized, cross-over, PK…

RANDOMIZED TRIAL OF BICTEGRAVIR OR DOLUTEGRAVIR WITH FTC/TAF FOR INITIAL HIV THERAPY

Because of their potency and safety, integrase strand transfer inhibitors (INSTIs) are widely recommended initial HIV-1 treatments in most major treatment guidelines. Bictegravir (BIC, GS-9883) is a novel, unboosted, once-daily INSTI that demonstrated potent activity in a 10-day monotherapy study and has in vitro activity against most INSTI-resistant viruses. Treatment naïve, HIV-infected adults were randomized…

INVESTIGATING THE ROLE OF TCR STRUCTURE IN FUNCTIONAL ACTIVITY OF HIV-SPECIFIC CTLs

Lentiviral vectors expressing effective HIV-specific TCR clonotypes can transform naïve CD8+ T cells into potent HIV-specific CTLs, a possible gene therapy approach to increase HIV-specific immunity. To optimize this approach, it is crucial to identify TCR clonotypes which confer the most potent anti-HIV activity. CTLs with superior antiviral efficacy, termed effective CTLs, are well-represented in…

TREATMENT OF ACUTE HIV INFECTION IN NEONATES

Antiretroviral therapy (ART) initiated soon after primary infection is thought to influence seeding of the viral reservoir with beneficial effects for virologic control. Infants are an important group who can be identified soon after infection. Here we describe virologic dynamics following early ART in infants. For the past 2 years, HIV PCR testing has been…

LOPINAVIR/RITONAVIR 1:1 SUPER-BOOSTING OVERCOMES RIFAMPICIN INTERACTIONS IN CHILDREN

Lopinavir/ritonavir 4:1 (LPV/r) is important in 1st-line antiretroviral therapy for infants. In high-burden settings, rifampicin based co-treatment for tuberculosis (TB) is often needed, but causes significant drug interactions. Superboosting LPV/r with ritonavir for a 1:1 ratio is considered effective, based on pharmacokinetic (PK) studies in 15 children. In an open-label, prospective study at 5 South…